A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
NCT03633708
This study is recruiting at 5 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Secondary Hyperparathyroidism
- Chronic Kidney Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 0 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Amgen
- Last updated on ClinicalTrials.gov
- February 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Childrens Hospital of Los Angeles · Los Angeles, CA
Missouri · 1
- Childrens Mercy Hospital · Kansas City, MO
Ohio · 1
- Cleveland Clinic Foundation · Cleveland, OH
Pennsylvania · 1
- Childrens Hospital of Philadelphia · Philadelphia, PA
Utah · 1
- Primary Childrens Hospital Outpatient Services · Salt Lake City, UT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.